Systematic review, meta-analysis and economic modelling of ...
Share Embed Flag
Download ePaper

Systematic review, meta-analysis and economic modelling of ...

Systematic review, meta-analysis and economic modelling of ... Systematic review, meta-analysis and economic modelling of ...

nihr.ac.uk
10.07.2015 Views

Assessment of diagnostic and prognostic accuracyTABLE 11 Population characteristics of studies of IMAStudy Study typePopulation: age (years);sex Inclusion criteria Exclusion criteriaTime fromsymptoms(hours)No. ofpatientsChristenson Multicentre, USA Mean age 59.1 (SD 14.8);2001 61 112 (50%) maleArrival at ED within 3 hours of clinicalsigns and symptoms of ACSMI > 3 hours before presentation,inconsistencies between cTnI andother biochemical marker data inthe 6- to 24-hour time frame< 3 hours 224Collinson 2006 48 Single centre, UK Median age 51.9; 335 (62%)maleAdmissions to the ED withundifferentiated chest painSignificant new ECG changes,requiring hospital admission, knownCAD with unstable angina, clearlynon-cardiac chest pain6 (median) 538Hjortshoj 2010 68 Single centre, UK Median range across threegroups (60–63); 70 (65%)maleChest pain and suspected of ACS None reported Not stated 107Keating 2006 70 Multicentre, UK Median age 61; 251/399eligible (63%) malePossible ischaemic cardiac chest painand normal ECGPain > 8 hours on admission,pain ceased > 2 hours previously,pregnant, renal replacementtherapy, jaundiceNot stated 27742NIHR Journals Library

DOI: 10.3310/hta17010 Health Technology Assessment 2013 Vol. 17 No. 1TABLE 12 Index and reference standard tests used in studies of IMAStudy Index test analyser Threshold Reference test assay and timingChristenson 2001 61 Albumin Cobalt Binding (ACBTM)Test (Ischemia Technologies, Denver,CO, USA) on a Cobas MIRA Plusinstrument75 U/ml Vitros ECi, Abbott AxSYM or Dimension RxL TnIat 6–24 hoursCollinson 2006 48 ACB assay (Ischemia Technologies,Denver, CO, USA)85 U/ml Roche Elecsys TnT or Beckman Coulter TnI up to72 hoursHjortshoj 2010 68 ACB test (Inverness MedicalInnovations Inc., Stirling, UK) on aCobas MIRA Plus instrument88.2 U/ml and91 U/mlRoche Elecsys TnT after 6–9 hours, and12–24 hoursKeating 2006 70 Beckman LX 20 86 U/ml TnI; Beckman Access; taken at least 8 hours afterpain onsetReference Tn diagnosticthreshold (µg/l)MI prevalence insample (%)0.8, 1.6 and 1.5, respectively 130.05 70.03 330.06 15© Queen’s Printer and Controller of HMSO 2013. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by the Secretary of Statefor Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journalsprovided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should beaddressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton SciencePark, Southampton SO16 7NS, UK.43

DOI: 10.3310/hta17010 Health Technology Assessment 2013 Vol. 17 No. 1TABLE 12 Index <strong>and</strong> reference st<strong>and</strong>ard tests used in studies <strong>of</strong> IMAStudy Index test analyser Threshold Reference test assay <strong>and</strong> timingChristenson 2001 61 Albumin Cobalt Binding (ACBTM)Test (Ischemia Technologies, Denver,CO, USA) on a Cobas MIRA Plusinstrument75 U/ml Vitros ECi, Abbott AxSYM or Dimension RxL TnIat 6–24 hoursCollinson 2006 48 ACB assay (Ischemia Technologies,Denver, CO, USA)85 U/ml Roche Elecsys TnT or Beckman Coulter TnI up to72 hoursHjortshoj 2010 68 ACB test (Inverness MedicalInnovations Inc., Stirling, UK) on aCobas MIRA Plus instrument88.2 U/ml <strong>and</strong>91 U/mlRoche Elecsys TnT after 6–9 hours, <strong>and</strong>12–24 hoursKeating 2006 70 Beckman LX 20 86 U/ml TnI; Beckman Access; taken at least 8 hours afterpain onsetReference Tn diagnosticthreshold (µg/l)MI prevalence insample (%)0.8, 1.6 <strong>and</strong> 1.5, respectively 130.05 70.03 330.06 15© Queen’s Printer <strong>and</strong> Controller <strong>of</strong> HMSO 2013. This work was produced by Goodacre et al. under the terms <strong>of</strong> a commissioning contract issued by the Secretary <strong>of</strong> Statefor Health. This issue may be freely reproduced for the purposes <strong>of</strong> private research <strong>and</strong> study <strong>and</strong> extracts (or indeed, the full report) may be included in pr<strong>of</strong>essional journalsprovided that suitable acknowledgement is made <strong>and</strong> the reproduction is not associated with any form <strong>of</strong> advertising. Applications for commercial reproduction should beaddressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials <strong>and</strong> Studies Coordinating Centre, Alpha House, University <strong>of</strong> Southampton SciencePark, Southampton SO16 7NS, UK.43

logo

products

Resources

Company

Terms of service
Privacy policy
Cookie policy
Cookie settings
Imprint
Change language
Made with love in Switzerland
© 2024 Yumpu.com all rights reserved

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!